Compare · AMGN vs EIGR
AMGN vs EIGR
Side-by-side comparison of Amgen Inc. (AMGN) and Eiger BioPharmaceuticals Inc. (EIGR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and EIGR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN carries a market cap of $240.11B.
- AMGN has hit the wire 22 times in the past 4 weeks while EIGR has been quiet.
- AMGN has more recent analyst coverage (25 ratings vs 1 for EIGR).
- Company
- Amgen Inc.
- Eiger BioPharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $240.11B
- -
- 1M return
- +0.64%
- -
- 1Y return
- +28.80%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2014
- News (4w)
- 22
- 0
- Recent ratings
- 25
- 1
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Eiger BioPharmaceuticals Inc.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.
Latest AMGN
- AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
- FDA Approval for KANJINTI issued to AMGEN INC
- Director Ishrak Omar was granted 152 shares, increasing direct ownership by 2% to 7,682 units (SEC Form 4)
- Director Holley Charles M was granted 185 shares, increasing direct ownership by 1% to 13,262 units (SEC Form 4)
- Director Gibbs David W was granted 278 shares (SEC Form 4)
- Director Drake Michael V was granted 114 shares, increasing direct ownership by 2% to 6,030 units (SEC Form 4)
- NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
- FDA Approval for AMJEVITA issued to AMGEN INC
- REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY
Latest EIGR
- SEC Form SC 13G/A filed by Eiger BioPharmaceuticals Inc. (Amendment)
- SEC Form 8-K filed by Eiger BioPharmaceuticals Inc.
- SEC Form 8-K filed by Eiger BioPharmaceuticals Inc.
- SEC Form 10-K/A filed by Eiger BioPharmaceuticals Inc. (Amendment)
- SEC Form 10-K filed by Eiger BioPharmaceuticals Inc.
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket
- Eiger Biopharmaceuticals Says On April 2, Received Notice From Nasdaq That Co's Common Stock Will Be Delisted From Nasdaq; Common Stock Is Expected To Begin Trading On Over-Counter Market On April 11